Serotonin transporter inhibition attenuates l-DOPA-induced dyskinesia without compromising l-DOPA efficacy in hemi-parkinsonian rats

European Journal of Neuroscience

Volumn 36, Issue 6, 2012, Pages 2839-2848

  Bishop, Christopher ^a   George, Jessica A ^a   Buchta, William ^a   Goldenberg, Adam A ^a   Mohamed, Mohamed ^a   Dickinson, Sando O ^a   Eissa, Satie ^a   Eskow Jaunarajs, Karen L ^a  

^a BINGHAMTON UNIVERSITY   (United States)

Author keywords

Abnormal involuntary movements; Dopamine; Parkinson's disease; Selective serotonin reuptake inhibitors

Indexed keywords

APOMORPHINE; BENSERAZIDE; CITALOPRAM; FLUOXETINE; LEVODOPA; OXIDOPAMINE; PAROXETINE; SEROTONIN UPTAKE INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACTIVITY; DRUG EFFICACY; DRUG SAFETY; DYSKINESIA; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HORMONE METABOLISM; MALE; MOTOR PERFORMANCE; NONHUMAN; OUTCOME ASSESSMENT; PARKINSON DISEASE; PRIORITY JOURNAL; RAPHE NUCLEUS; RAT; SEROTONIN BRAIN LEVEL;

ANIMALS; ANTIPARKINSON AGENTS; APOMORPHINE; BIOGENIC MONOAMINES; CITALOPRAM; CORPUS STRIATUM; DYSKINESIA, DRUG-INDUCED; FLUOXETINE; LEVODOPA; MALE; PARKINSONIAN DISORDERS; PAROXETINE; RAPHE NUCLEI; RATS; RATS, SPRAGUE-DAWLEY; SEROTONIN UPTAKE INHIBITORS;

EID: 84866412870     PISSN: 0953816X     EISSN: 14609568     Source Type: Journal    
DOI: 10.1111/j.1460-9568.2012.08202.x     Document Type: Article

References (70)

1. Ahlskog, J.E. & Muenter, M.D. (2001) Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov. Disord., 16, 448-458.
2. Arai, R., Karasawa, N., Geffard, M. & Nagatsu, I. (1995) l-DOPA is converted to dopamine in serotonergic fibers of the striatum of the rat: a double-labeling immunofluorescence study. Neurosci. Lett., 195, 195-198.
3. Bara-Jimenez, W., Bibbiani, F., Morris, M.J., Dimitrova, T., Sherzai, A., Mouradian, M.M. & Chase, T.N. (2005) Effects of serotonin 5-HT1A agonist in advanced Parkinson's disease. Mov. Disord., 20, 932-936.
4. Birkmayer, W. & Hornykiewicz, O. (1961) The L-3, 4-dioxyphenylalanine (DOPA)-effect in Parkinson-akinesia. Wien. Klin. Wochenschr., 73, 787-788.
5. Bishop, C., Taylor, J.L., Kuhn, D.M., Eskow, K.L., Park, J.Y. & Walker, P.D. (2006) MDMA and fenfluramine reduce l-DOPA-induced dyskinesia via indirect 5-HT1A receptor stimulation. Eur. J. Neurosci., 23, 2669-2676.
6. Bishop, C., Krolewski, D.M., Eskow, K.L., Barnum, C.J., Dupre, K.B., Deak, T. & Walker, P.D. (2009) Contribution of the striatum to the effects of 5-HT1A receptor stimulation in l-DOPA-treated hemiparkinsonian rats. J. Neurosci. Res., 87, 1645-1958.
7. Björklund, A., Falck, B. & Stenevi, U. (1971) Classification of monoamine neurones in the rat mesencephalon: distribution of a new monoamine neurone system. Brain Res., 32, 269-285.
8. Bonifati, V., Fabrizio, E., Cipriani, R., Vanacore, N. & Meco, G. (1994) Buspirone in levodopa-induced dyskinesia. Clin. Neuropharmacol., 17, 73-82.
9. Bymaster, F.P., Zhang, W., Carter, P.A., Shaw, J., Chernet, E., Phebus, L., Wong, D.T. & Perry, K.W. (2002) Fluoxetine, but not other selective serotonin uptake inhibitors, increases norepinephrine and dopamine extracellular levels in prefrontal cortex. Psychopharmacology, 160, 353-361.
10. Caley, C.F. & Friedman, J.H. (1992) Does fluoxetine exacerbate Parkinson's disease?J. Clin. Psychiatry, 53, 278-282.
11. Carta, M., Carlsson, T., Kirik, D. & Björklund, A. (2007) Dopamine released from 5-HT terminals is the cause of l-DOPA-induced dyskinesia in parkinsonian rats. Brain, 130, 1819-1833.
12. Cenci, M.A., Whishaw, I.Q. & Schallert, T. (2002) Animal models of neurological deficits: how relevant is the rat. Nat. Rev. Neurosci., 3, 574-579.
13. Ceravolo, R., Nuti, A., Piccinni, A., Dell'Agnello, G., Bellini, G., Gambaccini, G., Dell'Osso, L., Murri, L. & Bonuccelli, U. (2000) Paroxetine in Parkinson's disease: effects on motor and depressive symptoms. Neurology, 55, 1216-1218.
14. Chang, J.W., Wachtel, S.R., Young, D. & Kang, U.J. (1999) Biochemical and anatomical characterization of forepaw adjusting steps in rat models of Parkinson's disease: studies on medial forebrain bundle and striatal lesions. Neuroscience, 88, 617-628.
15. Chung, K.A., Carlson, N.E. & Nutt, J.G. (2005) Short-term paroxetine treatment does not alter the motor response to levodopa in PD. Neurology, 64, 1797-1798.
16. Dekundy, A., Lundblad, M., Danysz, W. & Cenci, M.A. (2007) Modulation of l-DOPA-induced abnormal involuntary movements by clinically tested compounds: further validation of the rat dyskinesia model. Behav. Brain Res., 179, 76-89.
17. Di Chiara, G. & Gessa, G.L. (1978) Pharmacology and neurochemistry of apomorphine. Adv. Pharmacol. Chemother., 15, 87-160.
18. Dupre, K.B., Eskow, K.L., Negron, G. & Bishop, C. (2007) The differential effects of 5-HT(1A) receptor stimulation on dopamine receptor-mediated abnormal involuntary movements and rotations in the primed hemiparkinsonian rat. Brain Res., 1158, 135-143.
19. Durif, F., Vidailhet, M., Bonnet, A.M., Blin, J. & Agid, Y. (1995) Levodopa-induced dyskinesias are improved by fluoxetine. Neurology, 45, 1855-1858.
20. Eskow, K., Gupta, V., Alam, S., Park, J. & Bishop, C. (2007) The partial 5-HT1A agonist buspirone reduces the expression and development of l-DOPA-induced dyskinesia in rats and improves l-DOPA efficacy. Pharmacol. Biochem. Behav., 87, 306-314.
21. Eskow, K.L., Dupre, K.B., Barnum, C.J., Dickinson, S.O., Park, J.Y. & Bishop, C. (2009) The role of the dorsal raphe nucleus in the development, expression, and treatment of L-dopa-induced dyskinesia in hemiparkinsonian rats. Synapse, 63, 610-620.
22. Feyder, M., Bonito-Oliva, A. & Fisone, G. (2011) l-DOPA-induced dyskinesia and abnormal signaling in striatal medium spiny neurons: focus on dopamine D1 receptor-mediated transmission. Front. Behav. Neurosci., 5, 71.
23. Fox, S.H., Henry, B., Hill, M.P., Peggs, G., Crossman, A.P. & Brotchie, J.M. (2001) Neural mechanisms underlying peak-dose dyskinesia induced by levodopa and apomorphine are distinct: evidence from the effects of the alpha(2) adrenergic adrenoreceptor antagonist idazoxan. Mov. Disord., 16, 642-650.
24. de la Fuente-Fernández, R., Sossi, V., Huang, Z., Furtado, S., Lu, J.Q., Calne, D.B., Ruth, T.J. & Stoessl, A.J. (2004) Levodopa-induced changes in synaptic dopamine levels increase with progression of Parkinson's disease: implications for dyskinesias. Brain, 127, 2747-2754.
25. Gerfen, C.R. & Surmeier, D.J. (2011) Modulation of striatal projection systems by dopamine. Annu. Rev. Neurosci., 34, 441-466.
26. Goetz, C.G., Damier, P., Hicking, C., Laska, E., Müller, T., Olanow, C.W., Rascol, O. & Russ, H. (2007) Sarizotan as a treatment for dyskinesias in Parkinson's disease: a double-blind placebo-controlled trial. Mov. Disord., 22, 179-186.
27. Griebel, G., Rodgers, R.J., Perrault, G. & Sanger, D.J. (1997) Risk assessment behaviour: evaluation of utility in the study of 5-HT-related drugs in the rat elevated plus maze. Pharmacol. Biochem. Behav., 57, 817-827.
28. Honig, G., Jongsma, M.E., van der Hart, M.C. & Tecott, L.H. (2009) Chronic citalopram administration causes a sustained suppression of serotonin synthesis in the mouse forebrain. PLoS One, 4, e6797.
29. Huang, Y.Z., Rothwell, J.C., Lu, C.S., Chuang, W.L. & Chen, R.S. (2011) Abnormal bidirectional plasticity-like effects in Parkinson's disease. Brain, 134, 2312-2320.
30. Huot, P., Johnston, T.H., Lewis, K.D., Koprich, J.B., Reyes, M.G., Fox, S.H., Piggott, M.J. & Brotchie, J.M. (2011) Characterization of 3, 4-methylenedioxymethamphetamine (MDMA) enantiomers in vitro and in the MPTP-lesioned primate: R-MDMA reduces severity of dyskinesia, whereas S-MDMA extends duration of ON-time. J. Neurosci., 31, 7190-7198.
31. Iravani, M.M., Jackson, M.J., Kuoppamäki, M., Smith, L.A. & Jenner, P. (2003) 3, 4-methylenedioxymethamphetamine (ecstasy) inhibits dyskinesia expression and normalizes motor activity in 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine-treated primates. J. Neurosci., 23, 9107-9115.
32. Johnston, T.H., Millar, Z., Huot, P., Wagg, K., Thiele, S., Salomonczyk, D., Yong-Kee, C.J., Gandy, M.N., McIldowie, M., Lewis, K.D., Gomez-Ramirez, J., Lee, J., Fox, S.H., Martin-Iverson, M., Nash, J.E., Piggott, M.J. & Brotchie, J.M. (2012) A novel MDMA analogue, UWA-101, that lacks psychoactivity and cytotoxicity, enhances l-DOPA benefit in parkinsonian primates. FASEB J., 26, 2154-2163.
33. Kannari, K., Tanaka, K., Maeda, T., Tomiyama, M., Suda, T. & Matsunaga, M. (2000) Reserpine treatment prevents increases in extracellular striatal dopamine following l-DOPA administration in ras with nigrostriatal denervation. J. Neurochem., 74, 263-269.
34. Kannari, K., Shen, H., Arai, A., Tomiyama, M. & Baba, M. (2006) Reuptake of l-DOPA-derived extracellular dopamine in the striatum with dopaminergic denervation via serotonin transporters. Neurosci. Lett., 402, 62-65.
35. Kilpatrick, I.C., Jones, M.W. & Phillipson, O.T. (1986) A semiautomated analysis method for catecholamines, indoleamines, and some prominent metabolites in microdissected regions of the nervous system: an isocratic HPLC technique employing coulometric detection and minimal sample preparation. J. Neurochem., 46, 1865-1876.
36. Kreiss, D.S. & Lucki, I. (1994) Differential regulation of serotonin (5-HT) release in the striatum and hippocampus by 5-HT1A autoreceptors of the dorsal and median raphe nuclei. J. Pharmacol. Exp. Ther., 269, 1268-1279.
37. Kuan, W.L., Zhao, J.W. & Barker, R.A. (2008) The role of anxiety in the development of levodopa-induced dyskinesias in an animal model of Parkinson's disease, and the effect of chronic treatment with the selective serotonin reuptake inhibitor citalopram. Psychopharmacology, 197, 279-293.
38. Larsen, M.B., Sonders, M.S., Mortensen, O.V., Larson, G.A., Zahniser, N.R. & Amara, S.G. (2011) Dopamine transport by the serotonin transporter: a mechanistically distinct mode of substrate translocation. J. Neurosci., 31, 6605-6615.
39. Leo, R.J. (1996) Movement disorders associated with the serotonin selective reuptake inhibitors. J. Clin. Psychiatry, 57, 449-454.
40. Lightowler, S., Kennett, G.A., Williamson, I.J.R., Blackburn, T.P. & Tullock, I.F. (1994) Anxiolytic-like effect of paroxetine in a rat social interaction test. Pharmacol. Biochem. Behav., 49, 281-285.
41. Lindenbach, D., Ostock, C.Y., Eskow Jaunarajs, K.L., Dupre, K.B., Barnum, C.J., Bhide, N. & Bishop, C. (2011) Behavioral and cellular modulation of l-DOPA-induced dyskinesia by β-adrenoceptor receptor blockade in the 6-OHDA lesioned rat. J. Pharmacol. Exp. Ther., 337, 755-765.
42. Lindgren, H.S., Andersson, D.R., Lagerkvist, S., Nissbrandt, H. & Cenci, M.A. (2010) l-DOPA-induced dopamine efflux in the striatum and the substantia nigra in a rat model of Parkinson's disease: temporal and quantitative relationship to the expression of dyskinesia. J. Neurochem., 112, 1465-1476.
43. Lundblad, M., Andersson, M., Winkler, C., Kirik, D., Wierup, N. & Cenci, M.A. (2002) Pharmacological validation of behavioural measures of akinesia and dyskinesia in a rat model of Parkinson's disease. Eur. J. Neurosci., 15, 120-132.
44. Maeda, T., Nagata, K., Yoshida, Y. & Kannari, K. (2005) Serotonergic hyperinnervation into the dopaminergic denervated striatum compensates for dopamine conversion from exogenously administered l-DOPA. Brain Res., 1046, 230-233.
45. Montastruc, J.-L., Fabre, N., Blin, O., Senard, J.-M., Rascol, O. & Rascol, A. (1995) Does fluoxetine aggravate Parkinson's disease? A pilot prospective study. Mov. Disord., 10, 355-357.
46. Muñoz, A., Li, Q., Gardoni, F., Marcello, E., Qin, C., Carlsson, T., Kirik, D., Di Luca, M., Björklund, A., Bezard, E. & Carta, M. (2008) Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of l-DOPA-induced dyskinesia. Brain, 131, 3380-3394.
47. Navailles, S., Bioulac, B., Gross, C. & De Deurwaerdère, P. (2010) Serotonergic neurons mediate ectopic release of dopamine induced by L-DOPA in a rat model of Parkinson's disease. Neurobiol. Dis., 38, 136-143.
48. Ng, K.Y., Chase, T.N., Colburn, R.W. & Kopin, I.J. (1970) l-DOPA-induced release of cerebral monoamines. Science, 170, 76-77.
49. Nutt, J.G. & Nygaard, T.G. (2011) Reponse to levodopa treatment in dopa-responsive dystonia. Arch. Neurol., 58, 905-910.
50. Nutt, J.G., Obeso, J.A. & Stocchi, F. (2000) Continuous dopamine receptor stimulation in advanced Parkinson's disease. Trends Neurosci., 23, S109-S115.
51. Olsson, M., Nikkhah, G., Bentlage, C. & Björklund, A. (1995) Forelimb akinesia in the rat Parkinson model: differential effects of dopamine agonists and nigral transplants as assessed by a new stepping test. J. Neurosci., 15, 3863-3875.
52. Owens, M.J., Morgan, W.N., Plott, S.J. & Nemeroff, C.B. (1997) Neurotransmitter receptor and transporter binding profile of antidepressants and their metabolites. J. Pharmacol. Exp. Ther., 283, 1305-1322.
53. Papathanou, M., Rose, S., McCreary, A. & Jenner, P. (2011) Induction and expression of abnormal involuntary movements is related to the duration of dopaminergic stimulation in 6-OHDA-lesioned rats. Eur. J. Neurosci., 33, 2247-2254.
54. Paxinos, G. & Watson, W. (1998) The Rat Brain in Stereotaxic Coordinates, 4th edn. Academic Press, San Diego.
55. Perry, K.W. & Fuller, R.W. (1992) Effect of fluoxetine on serotonin and dopamine concentration in microdialysis fluid from rat striatum. Life Sci., 50, 1683-1690.
56. Putterman, D.B., Munhall, A.C., Kozell, L.B., Belknap, J.K. & Johnson, S.W. (2007) Evaluation of levodopa dose and magnitude of dopamine depletion as risk factors for levodopa-induced dyskinesia in a rat model of Parkinson's disease. J. Pharmacol. Exp. Ther., 323, 277-284.
57. Rampello, L., Chiechio, S., Raffaele, R., Vecchio, I. & Nicoletti, F. (2002) The SSRI, citalopram, improves bradykinesia in patients with Parkinson's disease treated with L-dopa. Clin. Neuropharmacol., 25, 21-24.
58. Richard, I.H. & Kurlan, R. (1997) A survey of antidepressant drug use in Parkinson's disease. Parkinson Study Group. Neurology, 49, 1168-1170.
59. Rylander, D., Parent, M., O'Sullivan, S.S., Dovero, S., Lees, A.J., Bezard, E., Descarries, L. & Cenci, M.A. (2010) Maladaptive plasticity of serotonin axon terminals in levodopa-induced dyskinesia. Ann. Neurol., 68, 619-628.
60. Schallert, T., De Ryck, M., Whishaw, I.Q., Ramirez, V.D. & Teitelbaum, P. (1979) Excessive bracing reactions and their control by atropine and L-DOPA in an animal analog of Parkinsonism. Exp. Neurol., 64, 33-43.
61. Smith, Y., Wichmann, T., Factor, S.A. & DeLong, M.R. (2012) Parkinson's disease therapeutics: new developments and challenges since the introduction of levodopa. Neuropsychopharmacology, 37, 213-246.
62. Steur, E.N. (1993) Increase of Parkinson disability after fluoxetine medication. Neurology, 43, 211-213.
63. Szewczyk, B., Poleszak, E., Wlaź, P., Wróbel, A., Blicharska, E., Cichy, A., Dybała, M., Siwek, A., Pomierny-Chamioło, L., Piotrowska, A., Brański, P., Pilc, A. & Nowak, G. (2009) The involvement of serotonergic system in the antidepressant effect of zinc in the forced swim test. Prog. Neuropsychopharmacol. Biol. Psychiatry, 33, 323-329.
64. Tatsumi, M., Groshan, K., Blakely, R.D. & Richelson, E. (1997) Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur. J. Pharmacol., 340, 249-258.
65. Troiano, A.R., de la Fuente-Fernandez, R., Sossi, V., Schulzer, M., Mak, E., Ruth, T.J. & Stoessl, A.J. (2009) PET demonstrates reduced dopamine transporter expression in PD with dyskinesias. Neurology, 72, 1211-1216.
66. Verhagen Metman, L., Locatelli, E.R., Bravi, D., Mouradian, M.M. & Chase, T.N. (1997) Apomorphine responses in Parkinson's disease and the pathogenesis of motor complications. Neurology, 48, 369-372.
67. Weintraub, D., Moberg, P.J., Duda, J.E., Katz, I.R. & Stern, M.B. (2003) Recognition and treatment of depression in Parkinson's disease. J. Geriatr. Psychiatry Neurol., 16, 178-183.
68. Yamato, H., Kannari, K., Shen, H., Suda, T. & Matsunaga, M. (2001) Fluoxetine reduces l-DOPA-derived extracellular DA in the 6-OHDA-lesioned rat striatum. NeuroReport, 12, 1123-1126.
69. Zhang, X., Andren, P.E., Greengard, P. & Svenningsson, P. (2008) Evidence for a role of the 5-HT1B receptor and its adaptor protein, p11, in l-DOPA treatment of an animal model of Parkinsonism. Proc. Natl. Acad. Sci. USA, 105, 2163-2168.
70. Zigmond, M.J., Acheson, A.L., Stachowiak, M.K. & Stricker, E.M. (1984) Neurochemical compensation after nigrostriatal bundle injury in an animal model of preclinical parkinsonism. Arch. Neurol., 41, 856-861.